Table 1 Clinicopathological characteristics of all patient cohorts
GC | Training | Testing | Validation | |
|---|---|---|---|---|
Cohort | NAC [11] | TCGA [12] | UTSW | PCC |
N | 223 | 405 | 94 | 255 |
Tissue | TURBT | RC | RC | TURBT |
Expression data | Array | RNA-seq | Array | Array |
Age, median [IQR] | 62 (56–71) | 69 (60–76) | 70 (63–77) | NA |
Gender (%) | ||||
 Female | 69 (31%) | 106 (26%) | 16 (17%) | NA |
 Male | 154 (69%) | 299 (74%) | 78 (83%) | NA |
Clinical lymph node stage (%) | ||||
 cN0 | 140 (63%) | NA | 94 (100%) | NA |
 cN1–3 | 83 (37%) | NA | 0 (0%) | NA |
 cNx | 0 (0%) | NA | 0 (0%) | NA |
Clinical tumor stage (%) | ||||
 cTis/Ta | 0 (0%) | NA | 4 (4%) | NA |
 cT1 | 0 (0%) | NA | 10 (11%) | NA |
 cT2 | 90 (40%) | NA | 66 (70%) | NA |
 cT3 | 90 (40%) | NA | 9 (10%) | NA |
 cT4 | 43 (20%) | NA | 4 (4%) | NA |
 cTx | 0 (0%) | NA | 1 (1%) | NA |
Pathological tumor stage (%) | ||||
 ypT0/Tis/Ta/T1 | 103 (46%) | 0 (0%) | 1 (1%) | NA |
 ypT2 | 42 (19%) | 122 (30%) | 36 (38%) | NA |
 ypT3 | 50 (22%) | 193 (48%) | 42 (45%) | NA |
 ypT4 | 24 (11%) | 57 (14%) | 15 (16%) | NA |
 ypTx | 4 (2%) | 33 (8%) | 0 (0%) | NA |
Pathological lymph node stage (%) | ||||
 ypN0 | 138 (62%) | 235 (58%) | 62 (66%) | NA |
 ypN1–3 | 48 (21%) | 129 (32%) | 31 (33%) | NA |
 ypNx | 37 (17%) | 41 (10%) | 1 (1%) | NA |
FGFR3+ cases by GC (%) | 36 (16%) | 55 (14%) | 10 (11%) | 24 (11%) |
 of which n died during follow-up: | 2 | 9 | 1 | NA |